FDA-labeled indications for proposed treatments in IL-17-associated IBD.
| Condition | Risankizumab | Guselkumab | Ustekinumab | Infliximab | Upadacitinib | Tofacitinib |
|---|---|---|---|---|---|---|
| Plaque psoriasis | Yes | Yes | Yes | Yes | No | No* |
| Psoriatic arthritis | Yes | Yes | Yes | Yes | Yes* | Yes* |
| Ankylosing spondylitis | No | No | No | Yes | Yes* | Yes* |
| Nonradiographic axial spondyloarthritis | No | No | No | No* | Yes* | No |
| Crohn’s disease | Yes | No* | Yes | Yes | Yes* | No |
| Ulcerative colitis | Yes | Yes | Yes | Yes | Yes* | Yes* |
*May be used off-label, is under FDA applicational review, or additional requirements (e.g., disease severity criteria, prior therapy failure, or in combination with other medications) may apply. Refer to each drug’s prescribing information for detailed guidance.
The view(s) expressed herein are those of the author(s) and do not reflect the official policy or position of Joint Base Elmendorf-Richardson Medical Center, Brooke Army Medical Center, the U.S. Air Force and Army Medical Departments, the U.S. Air Force Office of the Surgeon General, the Department of the Air Force, the Department of the Army, Department of Defense or the U.S. Government.
During the preparation of this work, authors used ChatGPT to improve the readability and language. After using ChatGPT, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.
TLS: Conceptualization, Data curation, Writing—original draft. TAS: Investigation, Conceptualization, Writing—review & editing, Supervision. AP: Writing—review & editing, Supervision. All authors read and approved the submitted version.
The authors declare that they have no conflicts of interest.
This case report was conducted in accordance with the ethical standards set forth in the Declaration of Helsinki, as revised by the World Medical Association at its 75th General Assembly, Helsinki, Finland, in October 2024. Institutional Review Board (IRB) approval was waived by the Brooke Army Medical Center Human Research Protections Office (BAMC HRPO) / Regional Health Command-Central (RHC-C) Institutional Review Board and Ethics Committee, as the study involved only retrospective analysis of a single patient’s anonymized clinical data obtained during standard care, which is exempt from formal ethics review per institutional policy. Written informed consent was obtained from the patient for the endoscopic procedure, participation in this report, and publication of associated images and clinical details. All efforts were made to ensure patient confidentiality, including removal or generalization of all direct identifiers (e.g., name, date of birth, contact information, geographic details smaller than a state) and indirect identifiers (e.g., unique dates, rare disease descriptors) in compliance with HIPAA Privacy Rule standards (45 CFR §164.514) and institutional policy, ensuring that no information could reasonably be used to identify the individual.
Written informed consent to participate in the manuscript was obtained from the relevant patient.
Written informed consent to publication was obtained from the relevant patient.
This is a case report involving confidential patient data that cannot be publicly shared for privacy protection, despite informed consent for publication.
Not applicable.
© The Author(s) 2025.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.